Background: Trial Failure Triggers Stock Collapse and Lawsuit

Mereo BioPharma Group plc (NASDAQ: MREO) suffered a drastic 87.7% share price collapse after announcing that its two Phase 3 trials (ORBIT and COSMIC) for lead drug setrusumab in osteogenesis imperfecta failed to meet their primary endpoints (www.globenewswire.com). On December 29, 2025, Mereo revealed that neither trial achieved a statistically significant reduction in fracture rate versus control, despite showing improved bone mineral density (www.biospace.com). The stock plunged from $2.31 on December 26 to $0.29 on December 29, 2025 (www.globenewswire.com). In the aftermath, multiple shareholder class-action lawsuits have been filed alleging that Mereo misled investors about the trials’ prospects (www.globenewswire.com). During 2023–2025, executives had issued overwhelmingly positive statements – expressing confidence that setrusumab would “reduce fractures and improve quality of life” for patients (www.biospace.com) – while allegedly concealing adverse facts that neither Phase 3 would hit its primary goal (www.globenewswire.com). Investors who bought MREO shares between June 5, 2023 and December 26, 2025 are now being encouraged to seek lead plaintiff status before upcoming deadlines (April 6, 2026) in these class actions (www.prnewswire.com). This report examines Mereo’s fundamentals and outlook in light of these developments.

Dividend Policy & Yield

Mereo has never paid a dividend and does not anticipate doing so for the foreseeable future (www.sec.gov). As a clinical-stage biotech with no approved products, the company retains all capital to fund R&D rather than return cash to shareholders. Consequently, MREO’s dividend yield is 0%, and investors seeking income will find no payout here. Mereo explicitly states it intends to retain any future earnings to grow the business rather than distribute dividends (www.sec.gov). Under U.K. law, the company could only pay dividends out of accumulated profits, but Mereo’s accumulated losses make that impossible (see “Coverage” below). In short, no dividend history or AFFO/FFO metrics are applicable for MREO, given its developmental stage and focus on reinvestment.

Leverage and Debt Maturities

Mereo’s balance sheet carries minimal debt, relying overwhelmingly on equity financing. The company had used convertible notes for funding in prior years, but most have since converted to shares or been repaid. As of December 31, 2023, only about $4.4 million in convertible loan notes remained outstanding (non-current), down from $13.3 million a year earlier (www.mereobiopharma.com). This likely represents a convertible note held by Novartis that was extended to mature in February 2025 (www.sec.gov). Mereo amended that Novartis note, paying accrued interest and extending maturity (www.sec.gov), indicating proactive management of obligations. The company repaid its prior credit facility in full back in 2020, eliminating traditional bank debt (www.sec.gov). Consequently, Mereo’s leverage is very low – its debt-to-equity ratio is negligible, and there are no significant interest-bearing loans coming due aside from the small convertible note. With no long-term bank loans or bonds, Mereo’s financial risk from leverage is limited. The remaining convertible debt could convert to equity (if the stock price recovers above the conversion price) or require a cash payoff at maturity, but the principal amount is modest relative to the company’s cash reserves.

Coverage and Cash Flow

As an R&D-stage biotech, Mereo generates no positive earnings or cash flow, so traditional coverage metrics (like interest coverage or dividend coverage) are not meaningful. The company has operated at a loss each year since inception, funding its activities through investor capital. In 2023, Mereo’s net loss was approximately $29.5 million (improving from a $42.2 million loss in 2022) (www.mereobiopharma.com). Cumulatively, the company has an accumulated deficit of over $419 million as of year-end 2023 (www.mereobiopharma.com), reflecting the scale of historic losses. With negative operating cash flow, interest coverage is essentially zero – however, given the low debt, annual interest expense is minimal. The company’s strategy has been to raise equity or sell assets to fund operations, rather than rely on debt. Notably, Mereo recognized $10 million of revenue in 2023 from a one-time licensing payment (www.mereobiopharma.com), but it still incurred a significant operating loss. In sum, Mereo’s operations do not cover its expenses; it sustains itself via its cash reserves and external financing. There is no dividend to cover (as discussed above), and interest obligations on the tiny remaining debt are easily met from the cash on hand. The key “coverage” concern for investors is whether the cash runway is sufficient to cover R&D and overhead until the next value inflection point.

Valuation and Comparables

After the late-2025 crash, Mereo’s market capitalization has shrunk to roughly $80 million (uk.finance.yahoo.com). At ~$0.50 per share in early 2026, the stock trades about 83% below its pre-failure level (www.globenewswire.com). This valuation is only modestly above the company’s cash balance of $41 million (as of Dec 31, 2025) (www.biospace.com), implying an enterprise value of ~$39 million. In other words, nearly half of MREO’s market cap is backed by cash, and the market is assigning only a few tens of millions of dollars of value to Mereo’s pipeline and other assets. Traditional valuation multiples are not very useful given the lack of earnings – MREO has no P/E (trailing twelve-month EPS is –$0.25 and P/E is not applicable) (uk.finance.yahoo.com). Price-to-book is one gauge: Mereo’s shareholders’ equity was about $50.5 million at 2023 year-end (www.mereobiopharma.com), so the stock trades at ~1.5 times book value. This suggests the market is valuing the company only slightly above its liquidation value (cash + assets). Comparables: Many small-cap biotech peers with failed trials trade near cash value as well. The current MREO price reflects deep skepticism: investors are essentially pricing in that Mereo’s remaining drug candidates have uncertain value. By contrast, before the Phase 3 failure, MREO’s market cap exceeded $300 million, reflecting high expectations for setrusumab. Now, valuation is driven by downside protection (cash on hand) and optionality on any pipeline success. Until the company can demonstrate clear progress or partnerships for its remaining programs, upside will be speculative. Investors should note that standard metrics (P/E, EV/EBITDA, P/FFO) are not meaningful here – MREO trades on clinical milestones rather than fundamentals.

Risks and Red Flags

Mereo now faces significant risks and red flags that investors must weigh:

– Securities Class Action Lawsuits: The company is the target of class action suits alleging securities fraud. The complaint claims Mereo’s management misled investors by making upbeat statements about the Phase 3 trials while concealing material problems (www.globenewswire.com). For example, management repeatedly voiced confidence that setrusumab would hit its fracture-reduction goals (www.biospace.com), even as an interim analysis in mid-2025 showed no early success (and ultimately neither trial met endpoints). When the truth came out in December, shareholders suffered a massive loss (www.globenewswire.com). These lawsuits pose reputational and financial risk. While any settlement or judgment could be covered by insurance, the litigation will consume management attention and could deter some investors. The allegations also raise a red flag about management credibility – were executives overly promotional or negligent in assessing data? The outcome of the case (which will take time) is uncertain, but it adds an overhang for the stock.

– Major Pipeline Failure: The collapse of the setrusumab program is a critical blow. This drug for brittle bone disease (OI) was Mereo’s lead asset and primary value driver. Its failure to demonstrate efficacy on fractures dramatically undermines the company’s outlook. Mereo’s pipeline now rests on far earlier-stage or unproven assets. The next lead candidate, alvelestat (for alpha-1 antitrypsin deficiency lung disease), has shown promise in Phase 2 but still needs a Phase 3 trial. If alvelestat fails or is delayed, Mereo would be left with very little. The company does have a few partnered programs (e.g. vantictumab licensed to Āshibio for osteopetrosis, and leflutrozole for infertility with ReproNovo), but these are in early stages and contribute no near-term revenue. In short, Mereo’s risk profile is high – it is essentially a one-product company without that product now. The chance of total failure (if no pipeline candidate succeeds) is elevated, which could mean the remaining cash gets spent with little to show.

– Dependence on Partnerships: Mereo’s ability to advance its pipeline is heavily dependent on partners and external funding. Ultragenyx Pharmaceutical, Mereo’s partner on setrusumab, was funding and conducting the Phase 3 trials (www.biospace.com). Ultragenyx’s continued commitment is now in doubt – with the trials failing, Ultragenyx may choose to discontinue the program. If Ultragenyx walks away, Mereo cannot realistically fund a new trial in OI alone. Similarly, for alvelestat, Mereo has made it clear it is seeking a partner to co-fund Phase 3 development (www.biospace.com). If the company fails to secure a partnership, it may lack the resources or expertise to run a global Phase 3 on its own. This reliance on third parties is a risk: Mereo does not fully control its destiny. Losing a key partner or failing to find one would jeopardize its programs. Investors should watch for updates on partnership discussions as a barometer of pipeline viability.

– Financing and Dilution: Like most clinical biotechs, Mereo will likely need to raise more capital before it ever reaches profitability. The company claims its $41 million cash is sufficient to fund operations into mid-2027 at its now-reduced burn rate (www.biospace.com). However, that runway assumes minimal new trial spending. If Mereo commits to a costly Phase 3 trial (even with a partner sharing costs), or if timelines slip, cash could run short sooner. Historically, Mereo has repeatedly diluted shareholders to fund its work – for instance, its outstanding ordinary shares increased from ~625 million to ~701 million during 2023 (www.mereobiopharma.com), an ~12% jump due in part to note conversions and possibly equity issuance. Further equity raises at the current depressed stock price would be highly dilutive. The specter of dilution is thus a constant overhang. Additionally, the stock’s collapse pushed it below Nasdaq’s $1 minimum bid price; this creates a listing compliance risk. If MREO cannot regain compliance (e.g. through a price rebound or reverse stock split), it could eventually face delisting from the Nasdaq – another risk factor (though the company would have time and options to remedy this).

– Governance and Strategic Direction: There have been red flags in corporate governance and strategy. In 2022, an activist investor (Rubric Capital, owning ~14% at the time) launched a campaign criticizing Mereo’s governance and capital allocation (www.snowballresearch.com). Rubric argued for aggressive cost cuts, a review of assets, and even winding down clinical programs to return cash to shareholders (www.globenewswire.com). Mereo’s board fought off that proposal – asserting that an immediate wind-down “would only lead to questionable short-term value” (www.globenewswire.com) – and instead pledged to optimize its R&D spend and pursue its pipeline for longer-term gains (www.globenewswire.com). While Mereo did extend its cash runway and avoid liquidation, the very presence of that dispute signals shareholder dissatisfaction. Now that the lead program failed, those concerns may resurface. Investors must question whether management is making prudent decisions. Will they pivot strategies appropriately or cling to improbable science? The past activist pressure suggests that if the stock remains depressed, management could face renewed calls to unlock value (through asset sales, restructuring, or even a sale of the company). This uncertainty around leadership and strategy is another risk factor to monitor.

In sum, Mereo exhibits the high-risk profile typical of a small biotech with a binary outcome event that went against it. Legal troubles, pipeline setbacks, funding needs, and governance issues all represent dark clouds over the stock. Cautious investors should treat these red flags seriously when assessing MREO.

Open Questions and Outlook

Looking ahead, several critical questions remain open for Mereo BioPharma:

– Can Setrusumab Be Salvaged? Despite failing to meet the primary fracture endpoints, the ORBIT and COSMIC studies did show clinically meaningful improvements in bone mineral density (BMD) with high statistical significance (www.biospace.com). In the pediatric COSMIC trial, treated children saw a reduction in fracture rate versus the bisphosphonate control, though it narrowly missed statistical significance (www.biospace.com). Mereo is conducting additional analyses on the data (www.biospace.com). An open question is whether regulators would consider an alternate endpoint or subgroup approval. Could the strong BMD gains support a limited use approval in severe pediatric OI? Or perhaps a new trial design focusing on younger patients or longer follow-up could yet demonstrate fracture risk reduction? Management has expressed hope that there may be a path forward “especially in pediatrics given the totality of the data” (www.biospace.com). However, it’s uncertain if Ultragenyx or Mereo will commit more resources to this program. Investors will want to know if any discussions with health authorities or partners yield a viable plan for setrusumab – or if the drug will be shelved permanently. This is a major unknown that will shape Mereo’s future: is setrusumab dead, or can it rise from the ashes in some form?

– Will Ultragenyx Stay or Go? Ultragenyx Pharmaceutical (NASDAQ: RARE) has been Mereo’s pivotal partner for setrusumab, running the trials and presumably funding a large portion of them (www.biospace.com). Now that the outcome is negative, Ultragenyx’s intentions are unclear. One possibility is that Ultragenyx might terminate the collaboration to cut its losses, returning rights to Mereo (as often happens when partnered trials fail). Alternatively, Ultragenyx might still see enough potential (for example, in pediatric OI or with longer treatment) to continue exploring the drug, albeit likely with a redesigned study. The outlook for setrusumab largely depends on Ultragenyx’s stance – something neither company has publicly clarified yet beyond the initial data announcement. If Ultragenyx exits, Mereo would lose not only the partner’s expertise but also funding for that program. Investors are left to wonder: will Ultragenyx give setrusumab another chance, or walk away? Any decision or update from Ultragenyx in the coming months will be a key signal.

– Can Mereo Secure a Partner for Alvelestat? With setrusumab’s setback, alvelestat (an oral therapy for alpha-1 antitrypsin deficiency lung disease) becomes the lead program by default. Mereo has guided that it is Phase 3–ready and has aligned with regulators on trial design (www.biospace.com) – a global 18-month, ~220-patient study measuring lung function and symptoms (www.biospace.com). However, Mereo has also made clear it does not intend to launch this Phase 3 alone: management is “actively engaged with multiple potential partners” for alvelestat (www.biospace.com). The need for a partner is likely driven by cost and expertise – a Phase 3 respiratory trial will be expensive and complex. The open question is whether Mereo can attract a suitable partner (e.g. a larger pharma) and on what terms. A partnership could bring upfront cash and a share of costs, extending Mereo’s runway and validating the drug’s prospects. If no partner deal materializes, Mereo might face a tough choice: either significantly delay the Phase 3, attempt a smaller-scale study within its means (with uncertain success), or raise substantial capital to fund it – all suboptimal outcomes. Thus, the fate of alvelestat – arguably Mereo’s last big hope – hinges on partnership negotiations. Investors should watch for any licensing or co-development agreement as a potential catalyst. Until then, alvelestat remains an unproven asset that the market likely assigns only optional value.

– How Long Will the Cash Last (and Then What)? After sharp cost cuts, Mereo estimates its ~$41 million cash will sustain operations through mid-2027 under the current slimmed-down plan (www.biospace.com). This assumes the company keeps spending low – essentially maintaining necessary staff, doing analytical work, and advancing partnering discussions, but not initiating any new large trials on its own. The question is: what happens first, a value-creating event or running out of cash? If Mereo lands a partner or other funding (or perhaps wins a legal settlement or sells an asset), the runway could extend. Alternatively, if progress stalls, by 2027 the company might have to consider dilutive financing or strategic alternatives. Management has shown discipline in trimming expenses (e.g. halting pre-commercial manufacturing activities after the trial failure (www.biospace.com)). But even at a reduced burn, the clock is ticking. Essentially, Mereo has about a year and a half to either reboot its pipeline or find another solution before cash becomes critical. This raises a broader open question: will Mereo remain a going concern independently long enough to see another drug succeed? Or will the company be forced into a merger, sale, or wind-down to preserve remaining value? The prior activist pressure to “maximize value” suggests that if no clear progress is made, calls for strategic alternatives will grow louder. Management must navigate this tightrope – investing enough to potentially create value, while not overspending the cushion.

– Strategic Direction: Pivot, Partner, or Sell? Now that its flagship program has flopped, what is Mereo’s overarching strategy? Will it double down on rare disease drug development (betting on alvelestat and its other compounds) or pivot to a more conservative approach (such as monetizing assets and preserving cash)? The board and CEO Dr. Denise Scots-Knight have thus far signaled an intent to continue with the pipeline approach – focusing on rare disease candidates and seeking partnerships (www.mereobiopharma.com) (www.biospace.com). Yet investors may question if this is the wisest route. An alternative path would be to pursue a merger or acquisition. For example, Mereo could seek to be acquired by a larger biotech interested in its remaining programs (or in its Nasdaq listing and cash). Or it could merge with a peer to achieve better scale and diversification. Another option is asset sales: Mereo might sell rights to one of its programs (like alvelestat or its stake in setrusumab, if any remains) to raise cash and narrow its focus. These strategic choices remain open. The activist episode in 2022 revealed that at least some large shareholders favored a more drastic approach – e.g. winding down and distributing cash if prospects don’t improve (www.globenewswire.com). It’s unclear whether current management would entertain such an option now, but it cannot be ruled out if the outlook stays bleak. Thus, a key open question is: will Mereo persist as an independent developer, or pursue a strategic exit? The answer will depend on whether the company can reignite optimism through clinical or business development wins in the coming quarters.

Conclusion

Mereo BioPharma faces a challenging road ahead. The class action lawsuit deadlines (with lead plaintiff motions due by April 6, 2026) underscore the severity of the recent setback and the discontent of shareholders (www.prnewswire.com). Fundamentally, Mereo is a small biotech at a crossroads: it has no revenue-generating products, no dividend, and now no near-term Phase 3 success to tout. Its valuation has been crushed to essentially cash value, reflecting skepticism about management’s ability to deliver a win. Yet, the company is not without resources – it has cash to sustain a bit longer, it has at least one promising drug (alvelestat) in late-stage planning, and it has shown it can strike partnership deals (past alliances with Ultragenyx, Novartis, etc.). For investors, MREO is a high-risk, high-uncertainty situation. Key catalysts to watch will be any partnership announcements, further data releases or analyses for setrusumab, and developments in the class action (though the latter will likely play out slowly). Moreover, any signs of strategic shifts – such as a merger proposal or activist activity – could signal how value might ultimately be realized. Given the current landscape, potential investors should exercise caution. This Investor Alert emphasizes that those who incurred losses have avenues for legal recourse, and those considering the stock now should be aware of the substantial risks outlined. Mereo’s story in 2026 will depend on how these open questions are resolved – whether by scientific redemption, savvy deal-making, or structural change. Until clearer answers emerge, MREO remains a speculative gamble in the biotech space, with its fate hanging in the balance between promising science and the harsh realities of clinical failure.

Sources: The information in this report is based on Mereo BioPharma’s SEC filings, official press releases, and credible financial news. Key references include the company’s 20-F annual report (www.sec.gov), recent earnings and corporate update releases (www.biospace.com) (www.biospace.com), and GlobeNewswire/PR Newswire notices regarding the class action allegations (www.globenewswire.com) (www.globenewswire.com). These sources are cited inline throughout the report to ensure accuracy and provide direct support for the statements made.

For informational purposes only; not investment advice.